Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Aimee Bence, Lin"'
Autor:
Andrew Poole, Vijaykumar Karuppiah, Annabelle Hartt, Jaafar N. Haidar, Sylvie Moureau, Tomasz Dobrzycki, Conor Hayes, Christopher Rowley, Jorge Dias, Stephen Harper, Keir Barnbrook, Miriam Hock, Charlotte Coles, Wei Yang, Milos Aleksic, Aimee Bence Lin, Ross Robinson, Joe D. Dukes, Nathaniel Liddy, Marc Van der Kamp, Gregory D. Plowman, Annelise Vuidepot, David K. Cole, Andrew D. Whale, Chandramouli Chillakuri
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering
Externí odkaz:
https://doaj.org/article/d2f84672e7fe4eb3b7df368784cf9d36
Autor:
David Cole, Annelise Vuidepot, Andrew Whale, Andrew Poole, Vijaykumar Karuppiah, Annabelle Hartt, Jaafar Haidar, Sylvie Moureau, Aimee Bence Lin, Marc Van der Kamp, Gregory Plowman, Chandramouli Chillakuri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/f88c19af0c8e4b699fedf005b648101c
Autor:
Louis F. Stancato, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Peter J. Houghton, Raushan T. Kurmasheva, Brian P. Rubin, Douglas S. Hawkins, John M. Maris, Kristina A. Cole, Kateryna Krytska, Richard P. Beckmann, Aimee Bence Lin, Philip W. Iversen, Jennifer R. Stephens, Alle B. VanWye, Wayne Blosser, Matthew Renschler, Michele Dowless, Caitlin D. Lowery
Purpose:Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA-damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading to tumor cell death. Prexasertib (LY2606368) is a CHK1 small-molecule inhibitor und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f49e5209cc968b1be0066c56c47cfe
https://doi.org/10.1158/1078-0432.c.6528686
https://doi.org/10.1158/1078-0432.c.6528686
Autor:
Johanna Bendell, Cathy Eng, Aimee Bence Lin, Richard Beckmann, Sameera Wijayawardana, Ricardo Martinez, Wei Zhang, Lisa Golden, Jeffrey Infante, Funda Meric-Bernstam, Suzanne Jones, William N. William, Howard A. Burris, Stefan C. Grant, Manish Patel, Kathleen Moore, David S. Hong
Purpose: Prexasertib, a checkpoint kinase 1 inhibitor, demonstrated single-agent activity in patients with advanced squamous cell carcinoma (SCC) in the dose-escalation portion of a phase I study (NCT01115790). Monotherapy prexasertib was further eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3def8fc747f50b3c45f3e858cb77f444
https://doi.org/10.1158/1078-0432.c.6527487
https://doi.org/10.1158/1078-0432.c.6527487
Autor:
Louis F. Stancato, Aimee Bence Lin, Richard P. Beckmann, Jennifer Stephens, Julie Stewart, Beverly L. Falcon, Wayne Blosser, Michele Dowless, Alle B. VanWye, Caitlin D. Lowery
Supplemental methodology, specifically the in vitro cord formation assay and the enzyme-linked immunosorbent assay.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293c9b2e223ad6c5064eab5b446a0c96
https://doi.org/10.1158/1078-0432.22469084.v1
https://doi.org/10.1158/1078-0432.22469084.v1
Autor:
Johanna Bendell, Cathy Eng, Aimee Bence Lin, Richard Beckmann, Sameera Wijayawardana, Ricardo Martinez, Wei Zhang, Lisa Golden, Jeffrey Infante, Funda Meric-Bernstam, Suzanne Jones, William N. William, Howard A. Burris, Stefan C. Grant, Manish Patel, Kathleen Moore, David S. Hong
Supplementary Table S1. JTJA Study Dose Expansion Cohorts; Supplementary Table S2. Baseline Disease Classifications of SCCHN Patients Supplementary Table S3. Treatment-Emergent Adverse Events Related to Study Treatment in >10% of Patients with Any Tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f3dc0ee5f74c72052eb96db9362bb74
https://doi.org/10.1158/1078-0432.22470258.v1
https://doi.org/10.1158/1078-0432.22470258.v1
Autor:
Manish R. Patel, Aimee Bence Lin, Xuejing Wang, Andrew Capen, Yan Ding, Gregory P. Donoho, Wenjuan Wu, Suzanne Jones, Susanna V. Ulahannan, Judy S. Wang, Daniel D. Karp, Johanna C. Bendell, Kathleen N. Moore, David S. Hong
Compiled Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d01d24c1a0f1545ba7f1893d1517d2
https://doi.org/10.1158/1078-0432.22480382.v1
https://doi.org/10.1158/1078-0432.22480382.v1
Autor:
Louis F. Stancato, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Peter J. Houghton, Raushan T. Kurmasheva, Brian P. Rubin, Douglas S. Hawkins, John M. Maris, Kristina A. Cole, Kateryna Krytska, Richard P. Beckmann, Aimee Bence Lin, Philip W. Iversen, Jennifer R. Stephens, Alle B. VanWye, Wayne Blosser, Matthew Renschler, Michele Dowless, Caitlin D. Lowery
Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42becd965f45a14acf3708320f09beca
https://doi.org/10.1158/1078-0432.22474094
https://doi.org/10.1158/1078-0432.22474094
Autor:
Manish R. Patel, Aimee Bence Lin, Xuejing Wang, Andrew Capen, Yan Ding, Gregory P. Donoho, Wenjuan Wu, Suzanne Jones, Susanna V. Ulahannan, Judy S. Wang, Daniel D. Karp, Johanna C. Bendell, Kathleen N. Moore, David S. Hong
Purpose:Prexasertib, a checkpoint kinase 1 inhibitor (CHK1), exhibited modest monotherapy antitumor activity in previous studies. Preclinical data were generated to support the clinical combination of prexasertib + samotolisib, a PI3K/mTOR inhibitor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60c767cd4435f1384ad04106b060e79a
https://doi.org/10.1158/1078-0432.c.6530435.v1
https://doi.org/10.1158/1078-0432.c.6530435.v1
Autor:
Louis F. Stancato, Aimee Bence Lin, Richard P. Beckmann, Jennifer Stephens, Julie Stewart, Beverly L. Falcon, Wayne Blosser, Michele Dowless, Alle B. VanWye, Caitlin D. Lowery
Purpose: Checkpoint kinase 1 (CHK1) is a key regulator of the DNA damage response and a mediator of replication stress through modulation of replication fork licensing and activation of S and G2–M cell-cycle checkpoints. We evaluated prexasertib (L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace928a80491c543f787a72a8363ad6b
https://doi.org/10.1158/1078-0432.c.6527138.v1
https://doi.org/10.1158/1078-0432.c.6527138.v1